HS-10502 + docetaxel

HS-10502 + docetaxel is an investigational combination therapy under evaluation for advanced solid tumors. HS-10502 is a potent, selective oral inhibitor of Poly(ADP-ribose) polymerase 1 (PARP1), a crucial enzyme involved in DNA repair. Inhibiting PARP1 can potentiate the cytotoxic effect of DNA-damaging agents and is particularly effective in tumors with deficiencies in homologous recombination repair mechanisms (such as BRCA mutations). Docetaxel is a microtubule inhibitor widely used in cancer chemotherapy, which promotes microtubule assembly and inhibits their disassembly, leading to cell cycle arrest and apoptosis. The combination aims to leverage complementary mechanisms: docetaxel causes DNA and mitotic stress, while HS-10502 impairs DNA repair, potentially increasing cancer cell vulnerability, particularly in HRD-positive tumors. This combination is in phase 1 clinical trials for advanced solid tumors, including recurrent ovarian cancer, HER2-negative breast cancer, triple-negative breast cancer, advanced prostate cancer, and advanced gastric cancer[1][3].